Prevail Paste for Equine - SINGLE Syringe (30 gm) - [Anti-Inflammatory Solution]

Prevail Equine Paste is prescribed to treat horses for the pain and swelling associated with musculoskeletal disorders. This apple-flavored paste is a non-narcotic, non-steroidal, NSAID FDA approved for oral administration, and can provide relief for up to 36 hours.

Key Benefits

• Apple-flavored
• Controls inflammatory response
• NSAID approved for oral administration
• Non-narcotic
• Non-steroidal; no steroidal side effects
• Active up to 36 hours
• Safe: Approved by FDA

How it works

Flunixin meglumine is an analgesic, nonsteroidal, non-narcotic, and powerful agent that boasts antipyretic and anti-inflammatory benefits. It is far more powerful than codeine, meperidine, and pentazocine as an analgesic.

Indications

For the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

View Prevail Equine Paste Drug Facts Sheet.

The recommended dose of flunixin meglumine is 0.5 mg per lb of body weight once daily. The Prevail Equine Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs. One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.

Dosage:

The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.

Treatment may be given initially by intravenous or intramuscular injection of Prevail Injectable Solution, followed by Prevail Equine Paste on Days 2 to 5. Flunixin meglumine treatment should not exceed 5 consecutive days.

Caution:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Contraindications:

There are noknown contraindications to this drug when used as directed.

Precautions:

The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.

Side Effects:

During field studies with flunixin meglumine, no significant side effects were reported.

Toxicity:

No toxic effects were observed in rats given oral flunixin meglumine 2 mg/kg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg/kg. Flunixin was well tolerated in monkeys dosed daily with 4 mg/kg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg/lb for 5 consecutive days.

Storage:

Store at 20°C - 25°C (68°F - 77°F); excursions permitted between 15°C - 30°C (between 59°F - 86°F).